1 – 10 of 15
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Long-term follow-up of the randomized, prospective Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial
(
- Contribution to journal › Article
-
Mark
Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac Allograft Vasculopathy in Heart Transplant Recipients
(
- Contribution to journal › Article
- 2023
-
Mark
Pulmonary Hypertension Phenotype Can Be Identified in Heart Failure With Reduced Ejection Fraction Using Echocardiographic Assessment of Pulmonary Artery Pressure With Supportive Use of Pressure Reflection Variables
(
- Contribution to journal › Article
- 2022
-
Mark
Association between central haemodynamics and renal function in advanced heart failure : a nationwide study from Sweden
(
- Contribution to journal › Article
-
Mark
Longevity of anti-spike and anti-nucleocapsid antibodies after COVID-19 in solid organ transplant recipients compared to immunocompetent controls
(
- Contribution to journal › Article
- 2021
-
Mark
Initial Report From a Swedish High-volume Transplant Center After the First Wave of the COVID-19 Pandemic
(
- Contribution to journal › Article
-
Mark
COVID-19 in solid organ transplant recipients : A national cohort study from Sweden
(
- Contribution to journal › Article
- 2020
-
Mark
Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients : Long-term Follow-up From the Randomized SCHEDULE Study
(
- Contribution to journal › Article
-
Mark
Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients : Design of the randomized controlled EVOLVD trial
(
- Contribution to journal › Article
-
Mark
Randomized trial of a left ventricular assist device as destination therapy versus guideline-directed medical therapy in patients with advanced heart failure. Rationale and design of the SWEdish evaluation of left Ventricular Assist Device (SweVAD) trial
(
- Contribution to journal › Article